CL2014003237A1 - Formulación farmacéutica estable que comprende un anticuerpo anti-dll4 (ligando tipo delta humano 4); y kit que comprende la composición en un envase e instrucciones. - Google Patents

Formulación farmacéutica estable que comprende un anticuerpo anti-dll4 (ligando tipo delta humano 4); y kit que comprende la composición en un envase e instrucciones.

Info

Publication number
CL2014003237A1
CL2014003237A1 CL2014003237A CL2014003237A CL2014003237A1 CL 2014003237 A1 CL2014003237 A1 CL 2014003237A1 CL 2014003237 A CL2014003237 A CL 2014003237A CL 2014003237 A CL2014003237 A CL 2014003237A CL 2014003237 A1 CL2014003237 A1 CL 2014003237A1
Authority
CL
Chile
Prior art keywords
ligand
kit
package
instructions
composition
Prior art date
Application number
CL2014003237A
Other languages
English (en)
Inventor
Scott Walsh
Daniel Dix
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003237(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2014003237A1 publication Critical patent/CL2014003237A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
CL2014003237A 2012-05-31 2014-11-27 Formulación farmacéutica estable que comprende un anticuerpo anti-dll4 (ligando tipo delta humano 4); y kit que comprende la composición en un envase e instrucciones. CL2014003237A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261653478P 2012-05-31 2012-05-31

Publications (1)

Publication Number Publication Date
CL2014003237A1 true CL2014003237A1 (es) 2015-07-10

Family

ID=48670784

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003237A CL2014003237A1 (es) 2012-05-31 2014-11-27 Formulación farmacéutica estable que comprende un anticuerpo anti-dll4 (ligando tipo delta humano 4); y kit que comprende la composición en un envase e instrucciones.

Country Status (29)

Country Link
US (1) US9675692B2 (es)
EP (1) EP2854849B1 (es)
JP (1) JP6144758B2 (es)
KR (1) KR20150033615A (es)
CN (1) CN104349791A (es)
AR (1) AR092325A1 (es)
AU (1) AU2013267301B2 (es)
BR (1) BR112014028997A2 (es)
CA (1) CA2872275C (es)
CL (1) CL2014003237A1 (es)
CO (1) CO7151478A2 (es)
DK (1) DK2854849T3 (es)
EA (1) EA029779B1 (es)
ES (1) ES2668900T3 (es)
HK (1) HK1207305A1 (es)
IL (1) IL235468A0 (es)
LT (1) LT2854849T (es)
MA (1) MA37645B1 (es)
MX (1) MX357146B (es)
NO (1) NO2887943T3 (es)
NZ (1) NZ702288A (es)
PH (1) PH12014502429A1 (es)
PL (1) PL2854849T3 (es)
PT (1) PT2854849T (es)
SG (1) SG11201407171XA (es)
SI (1) SI2854849T1 (es)
TW (1) TWI609696B (es)
UY (1) UY34842A (es)
WO (1) WO2013181486A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2488204T3 (en) 2009-10-16 2016-06-06 Oncomed Pharm Inc Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
KR102091293B1 (ko) 2011-09-23 2020-03-20 온코메드 파마슈티칼스, 인크. Vegf/dll4 결합제 및 그의 용도
CN107530419B (zh) 2014-10-31 2021-05-18 昂考梅德药品有限公司 治疗疾病的组合疗法
EP3207936B1 (en) * 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
CN109071644B (zh) 2015-09-23 2023-09-19 昂考梅德药品有限公司 治疗癌症的方法和组合物
CN112165951A (zh) * 2018-04-16 2021-01-01 默克专利股份有限公司 用于改善热稳定性的蛋白质制剂添加剂
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
IL299152A (en) * 2020-07-08 2023-02-01 Regeneron Pharma Stabilized formulations that include antibodies against CTLA-4

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
ES2477996T3 (es) 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
EP1324776B2 (en) 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
KR20040085185A (ko) 2002-02-14 2004-10-07 추가이 세이야쿠 가부시키가이샤 항체함유 용액제제
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
PL1610820T5 (pl) 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2586459B1 (en) 2005-03-25 2017-05-24 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
AU2006259664A1 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
JP5216002B2 (ja) 2006-06-16 2013-06-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 硝子体内投与に適したｖｅｇｆアンタゴニスト製剤
JP2010507624A (ja) 2006-10-27 2010-03-11 アブリンクス エン．ヴェー． ポリペプチド及びタンパク質の鼻内送達
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
DK2488204T3 (en) * 2009-10-16 2016-06-06 Oncomed Pharm Inc Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
PT3721904T (pt) 2009-11-20 2021-11-15 Biocon Ltd Formulações de anticorpo t1h
EP3680253A3 (en) * 2010-03-02 2020-09-30 AbbVie Inc. Therapeutic dll4 binding proteins
EA034617B1 (ru) * 2010-10-06 2020-02-27 Ридженерон Фармасьютикалз, Инк. Дозированная форма жидкой фармацевтической композиции, содержащей антитела к рецептору интерлейкина-4 (il-4r)

Also Published As

Publication number Publication date
EA201492186A1 (ru) 2015-08-31
PH12014502429B1 (en) 2015-01-12
PT2854849T (pt) 2018-05-09
LT2854849T (lt) 2018-05-10
WO2013181486A1 (en) 2013-12-05
HK1207305A1 (en) 2016-01-29
UY34842A (es) 2013-12-31
DK2854849T3 (en) 2018-04-30
CA2872275C (en) 2021-05-18
EP2854849A1 (en) 2015-04-08
NO2887943T3 (es) 2018-05-05
US20130323260A1 (en) 2013-12-05
MX2014014363A (es) 2015-02-05
CA2872275A1 (en) 2013-12-05
MA37645A2 (fr) 2016-08-31
SG11201407171XA (en) 2014-11-27
PL2854849T3 (pl) 2018-07-31
TW201400130A (zh) 2014-01-01
PH12014502429A1 (en) 2015-01-12
ES2668900T3 (es) 2018-05-23
MA37645B1 (fr) 2018-10-31
JP6144758B2 (ja) 2017-06-07
AU2013267301B2 (en) 2018-02-08
EP2854849B1 (en) 2018-02-28
CO7151478A2 (es) 2014-12-29
BR112014028997A2 (pt) 2017-07-25
KR20150033615A (ko) 2015-04-01
JP2015520173A (ja) 2015-07-16
SI2854849T1 (en) 2018-05-31
EA029779B1 (ru) 2018-05-31
AR092325A1 (es) 2015-04-15
AU2013267301A1 (en) 2014-12-18
TWI609696B (zh) 2018-01-01
MX357146B (es) 2018-06-28
MA37645A3 (fr) 2017-07-31
US9675692B2 (en) 2017-06-13
NZ702288A (en) 2016-12-23
IL235468A0 (en) 2014-12-31
CN104349791A (zh) 2015-02-11

Similar Documents

Publication Publication Date Title
CL2014003237A1 (es) Formulación farmacéutica estable que comprende un anticuerpo anti-dll4 (ligando tipo delta humano 4); y kit que comprende la composición en un envase e instrucciones.
CL2014001930A1 (es) Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2).
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CL2014001047A1 (es) Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas.
FR2998570B1 (fr) Peptides, compositions les comprenant et utilisations notamment cosmetiques propigmentantes
CL2014002954A1 (es) Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos.
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
HK1199712A1 (en) 18-methyl-6,7-methylene-3-oxo-17-pregn-4-ene-21,17-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis 18--67--3--17--4--2117-
CL2014000844A1 (es) Formulacion farmaceutica oral de liberacion prolongada en forma de multiparticulas, que comprende a) 40-o-(2-hidroxi)etil-rapamicina y b) al menos un recubrimiento de liberacion prolongada.
IT1398930B1 (it) Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
BR112014020992A2 (pt) Composto,uso de composto na fabricação de um medicamento e composição farmacêutica
FR3000670B1 (fr) Composition cosmetique apaisante a base d'acide salicylique.
IL237345B (en) Antibody and drug conjugates (adc) that bind to 158p1d7 proteins, preparations containing them and their uses
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
CL2013000098A1 (es) Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso.
CL2014003503A1 (es) Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano.
SI2739615T1 (sl) Fenil-3-aza-biciklo(3.1.0)heks-3-il-metanoni in njihova uporaba kot zdravilo
HK1203947A1 (en) Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions (halofuginol)
BR112013003530A2 (pt) ''produto farmacêutico, kit, uso e preparações''
FR2958157B1 (fr) Composition cosmetique et pharmaceutique comprenant du n-acetyl-glucosamine-6-phosphate
CL2014003148A1 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.
IL240949B (en) Aqueous pharmaceutical formulation for use in the treatment of type 1 or type 2 juvenile diabetes
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
CL2013002905A1 (es) Composición farmacéutica que comprende fimasartan, una sal, solvato o hidrato del mismo y amlodipina, un isómero, sal, solvato o hidrato del mismo; uso en el tratamiento de hipertensión y enfermedades cardiovasculares.
BRPI0915527A2 (pt) pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos